Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are widely applied to treat EGFR-mutant non-small cell lung cancer (NSCLC). BIM is a BH3 domain-containing protein encoded by BCL2L11. Some EGFR-mutant NSCLC patients showing BIM deletion polymorphism are resistant to EGFR TKIs....

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Jinjing, Bai, Hao, Yan, Bo, Li, Rong, Shao, Minhua, Xiong, Liwen, Han, Baohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752461/
https://www.ncbi.nlm.nih.gov/pubmed/29312548
http://dx.doi.org/10.18632/oncotarget.19411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752461/
https://www.ncbi.nlm.nih.gov/pubmed/29312548
http://dx.doi.org/10.18632/oncotarget.19411

Ejemplares similares